ZyVersa Therapeutics, Inc.
For the period ended Oct 10, 2025. Filed Oct 15, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 10, 2025 · Filed Oct 15, 2025
Use the contents to explore the available documents and sections.
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): | October 10, 2025 |
|---|
ZYVERSA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-41184 | 86-2685744 |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 2200 N. Commerce Parkway, Suite 208, Weston, Florida | 33326 |
|---|---|
| (Address of principal executive offices) | (Zip Code) |
| Registrant’s telephone number, including area code: | (754) 231-1688 |
|---|
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.0001 per share | ZVSA | —(1) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| (1) | The Company’s common stock is quoted on the OTCQB® Venture Market under the symbol “ZVSA.” |
| Item 5.02 | Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On October 10, 2025, Pablo Guzman, M.D., resigned as Chief Medical Officer and Senior Vice President of Medical Affairs of ZyVersa Therapeutics, Inc. (the “Company”). Dr. Guzman first joined the Company in January 2015, following more than 35 years of practicing medicine/interventional cardiology in South Florida and serving as a managing partner of Cardiology Associates of Fort Lauderdale. Dr. Guzman resigned to spend more time with his family and to travel.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: October 15, 2025 | ZYVERSA THERAPEUTICS, INC. |
|---|---|
| /s/ Stephen Glover | |
| Stephen Glover | |
| Chief Executive Officer |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.